In fact, CAR-MAIT cells designed to target human EGF receptors (HER) and CD19 could kill, respectively, the breast cancer cell line MDA-231 ectopically expressing HER2, and T2 and NALM6 lymphoma cell lines expressing endogenous CD19 [49]. This evidence concerns the gene CD19 and lymphoma.